NAMS vs. SNDX, ARDX, GLPG, KROS, PTGX, AGIO, CPRX, HRMY, EVO, and SDGR
Should you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Galapagos (GLPG), Keros Therapeutics (KROS), Protagonist Therapeutics (PTGX), Agios Pharmaceuticals (AGIO), Catalyst Pharmaceuticals (CPRX), Harmony Biosciences (HRMY), Evotec (EVO), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
In the previous week, Syndax Pharmaceuticals had 5 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for Syndax Pharmaceuticals and 7 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.69 beat Syndax Pharmaceuticals' score of 0.39 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Syndax Pharmaceuticals' return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.
89.9% of NewAmsterdam Pharma shares are held by institutional investors. 4.1% of Syndax Pharmaceuticals shares are held by insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
NewAmsterdam Pharma has lower revenue, but higher earnings than Syndax Pharmaceuticals.
Syndax Pharmaceuticals presently has a consensus target price of $34.42, indicating a potential upside of 69.62%. NewAmsterdam Pharma has a consensus target price of $33.25, indicating a potential upside of 65.51%. Given NewAmsterdam Pharma's higher possible upside, equities research analysts clearly believe Syndax Pharmaceuticals is more favorable than NewAmsterdam Pharma.
Syndax Pharmaceuticals received 355 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.73% of users gave Syndax Pharmaceuticals an outperform vote.
Summary
NewAmsterdam Pharma beats Syndax Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewAmsterdam Pharma Competitors List
Related Companies and Tools
